Discover how trastuzumab emtansine (T-DM1), a next-generation HER2-targeted antibody–drug conjugate, delivers precision cytotoxic therapy in HER2-positive breast cancer, improves progression-free and overall survival, and reduces off-target toxicity compared with conventional chemotherapy.
Discover why KRAS was historically labeled “undruggable,” how covalent KRAS G12C inhibitors like sotorasib and adagrasib overcame structural challenges, and what this breakthrough means for treating KRAS-mutant cancers such as NSCLC, colorectal, and pancreatic tumors.
Learn what MRTX1133 is, how it selectively targets the KRAS G12D mutation, and why this first-in-class, non-covalent inhibitor is reshaping the landscape of precision oncology for pancreatic, colorectal, and lung cancers.
Discover why KRAS became the iconic “undruggable” oncogene in cancer biology, how covalent KRASG12C inhibitors like sotorasib and adagrasib opened the door, and what’s next for targeting common KRAS mutations such as G12D and G12V in lung, pancreatic, and colorectal cancers.
Discover how KRAS evolved from an “undruggable” oncogene to a validated drug target. Learn how covalent KRASG12C inhibitors like sotorasib and adagrasib work, and explore emerging noncovalent strategies for targeting other KRAS mutations in lung, colorectal, and pancreatic cancer.
Learn how PROTACs (Proteolysis-Targeting Chimeras) work, why they can target “undruggable” cancer proteins, and how small molecule degraders like ARV-110 and ARV-471 are changing oncology treatment.